Alpha¹ by KaimenConfidential

Kaimen Rigor review

Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial.

Sarraju A, Brennan D, Hayden K, Stronczek A, Goldberg AC, Michos ED, McGuire DK, Mason D, Tercek G, Nicholls SJ, Kling D, Neild AL, Kastelein J, Davidson M, Ditmarsch M, Nissen SE

DOI: 10.1016/S0140-6736(25)00721-4
Record issued: 2026-08-15
Engine: 7.39.0
Exported: 2026-09-20

Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/7dafeffa-3328-45df-a199-bb707f5f8678 is authoritative.

Kaimen Rigor review

Kaimen Rigor reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 17 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.
No data or code availability links were detected to verify.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy claim is based on LDL cholesterol reduction, a surrogate biomarker for cardiovascular outcomes. Although the paper cites prior evidence linking LDL cholesterol reduction to reduced ASCVD events, it does not demonstrate target engagement (e.g., PK/PD) at the tested dose in this trial, and the surrogate-to-clinical-outcome link is not validated within this study. The claim of clinical benefit is inferred from LDL lowering.
“Combination therapy of obicetrapib and ezetimibe significantly reduced LDL cholesterol. This oral, single-pill therapy could improve LDL cholesterol management in patients with pre-existing or high risk for ASCVD.”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 102OverreachOverstated conclusions 103AuthenticityData authenticity concerns 104DisclosureReporting gaps 05AvailabilityNone found · partly checked 06Copyedit4 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and well-reported Phase 3 randomized controlled trial with rigorous design, clear ethics approvals, and appropriate statistical methods. The main weaknesses are a vague data availability statement and minor reporting inconsistencies (e.g., missing explicit CONSORT reference, CI sign inconsistency in abstract).

Both reviewers independently scored all eight dimensions and agreed on all statuses; no divergence to reconcile. The study is a human interventional trial, so several sub-criteria (e.g., replicate distinction, controls, species/strain, housing, IACUC) are not applicable. The statistics verification recomputed 8 reported tests consistently, but this does not confirm all statistical results; the citation check found no retracted or unresolved references.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 8 tests: 8 consistent, 0 inconsistent; 8 via agent-written checks.

Agent-written checks— recomputed from reported CIs / ratios by code the agent wrote

CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 1
Primary endpoint: FDC vs placebo LDL reduction
“At day 84, the difference in the reduction of LDL cholesterol concentrations in the obicetrapib–ezetimibe FDC group was –48·6% (95% CI –58·3 to –38·9, p<0·0001) compared with the placebo treatment group”
Find in source
Taken as given: The estimate is a difference in means (not a ratio), so log=0.; The 95% CI is two-sided.; The p-value is two-sided.
Method: Recomputed two-sided p-value from the estimate and 95% CI using the normal approximation.
How we recomputed it: pCI(-48.6, -58.3, -38.9, 0)
CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 1
Primary endpoint: FDC vs ezetimibe LDL reduction
“–27·9% (–37·5 to –18·4, p<0·0001) compared with the ezetimibe monotherapy group”
Find in source
Taken as given: The estimate is a difference in means.; The 95% CI is two-sided.; The p-value is two-sided.
Method: Recomputed two-sided p-value from the estimate and 95% CI.
How we recomputed it: pCI(-27.9, -37.5, -18.4, 0)
CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 1
Primary endpoint: FDC vs obicetrapib LDL reduction
“–16·8% (–26·4 to –7·1, p=0·0007) compared with the obicetrapib monotherapy group”
Find in source
Taken as given: The estimate is a difference in means.; The 95% CI is two-sided.; The p-value is two-sided.
Method: Recomputed two-sided p-value from the estimate and 95% CI.
How we recomputed it: pCI(-16.8, -26.4, -7.1, 0)
CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 1
Primary endpoint: obicetrapib vs placebo LDL reduction
“The placebo-adjusted LDL cholesterol reduction in the obicetrapib monotherapy group was –31·9% (–41·6 to –22·1, p<0·0001).”
Find in source
Taken as given: The estimate is a difference in means.; The 95% CI is two-sided.; The p-value is two-sided.
Method: Recomputed two-sided p-value from the estimate and 95% CI.
How we recomputed it: pCI(-31.9, -41.6, -22.1, 0)
CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 2
Recompute p-value for FDC vs placebo LDL reduction from reported estimate and CI.
“At day 84, the difference in the reduction of LDL cholesterol concentrations in the obicetrapib–ezetimibe FDC group was –48·6% (95% CI –58·3 to –38·9, p<0·0001) compared with the placebo treatment group.”
Find in source
Taken as given: The estimate is the least-squares mean difference in percent change.; The CI is a 95% confidence interval.; The p-value is two-sided.
Method: Used pCI function to compute two-sided p from estimate and CI.
How we recomputed it: pCI(-48.6, -58.3, -38.9, 0)
CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 2
Recompute p-value for FDC vs ezetimibe LDL reduction from reported estimate and CI.
“At day 84, the difference in the reduction of LDL cholesterol concentrations in the obicetrapib–ezetimibe FDC group was –48·6% (95% CI –58·3 to –38·9, p<0·0001) compared with the placebo treatment group, –27·9% (–37·5 to –18·4, p<0·0001) compared with the ezetimibe monotherapy group”
Find in source
Taken as given: The estimate is the least-squares mean difference in percent change.; The CI is a 95% confidence interval.; The p-value is two-sided.
Method: Used pCI function to compute two-sided p from estimate and CI.
How we recomputed it: pCI(-27.9, -37.5, -18.4, 0)
CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 2
Recompute p-value for FDC vs obicetrapib LDL reduction from reported estimate and CI.
“At day 84, the difference in the reduction of LDL cholesterol concentrations in the obicetrapib–ezetimibe FDC group was –48·6% (95% CI –58·3 to –38·9, p<0·0001) compared with the placebo treatment group, –27·9% (–37·5 to –18·4, p<0·0001) compared with the ezetimibe monotherapy group, and –16·8% (–26·4 to –7·1, p=0·0007) compared with the obicetrapib monotherapy group.”
Find in source
Taken as given: The estimate is the least-squares mean difference in percent change.; The CI is a 95% confidence interval.; The p-value is two-sided.
Method: Used pCI function to compute two-sided p from estimate and CI.
How we recomputed it: pCI(-16.8, -26.4, -7.1, 0)
CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 2
Recompute p-value for obicetrapib vs placebo LDL reduction from reported estimate and CI.
“The placebo-adjusted LDL cholesterol reduction in the obicetrapib monotherapy group was –31·9% (–41·6 to –22·1, p<0·0001).”
Find in source
Taken as given: The estimate is the least-squares mean difference in percent change.; The CI is a 95% confidence interval.; The p-value is two-sided.
Method: Used pCI function to compute two-sided p from estimate and CI.
How we recomputed it: pCI(-31.9, -41.6, -22.1, 0)

lowinternal contradiction
The abstract reports the obicetrapib monotherapy vs placebo CI as (22·1 to 41·6) while the results section reports it as (–41·6 to –22·1). This is a sign inconsistency but not a numerical contradiction.
Abstract: 'Obicetrapib monotherapy decreased LDL cholesterol by 31·9% (22·1 to 41·6) versus placebo.' Results: 'The placebo-adjusted LDL cholesterol reduction in the obicetrapib monotherapy group was –31·9% (–41·6 to –22·1, p<0·0001).'
Abstractreviewer’s wording
lowinternal contradiction
The abstract states '177 (43%) were female' but Table 1 shows the sum of female counts across groups is 48+33+45+51=177, which is consistent. No contradiction.
“177 (43%) were female”
Table 1Find in source

Overstated conclusions

1 finding · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed

6 major claims checked against the paper's own evidence: all adequately supported.

supportedReviewer 1
The FDC of obicetrapib and ezetimibe significantly reduced LDL cholesterol compared with placebo, ezetimibe, and obicetrapib monotherapy.
The primary endpoint results directly support this claim with statistically significant differences and 95% CIs.
Evidence: Primary endpoint results: FDC vs placebo -48.6% (95% CI -58.3 to -38.9, p<0.0001); vs ezetimibe -27.9% (-37.5 to -18.4, p<0.0001); vs obicetrapib -16.8% (-26.4 to -7.1, p=0.0007).
At day 84, percent differences in LDL cholesterol reduction with the FDC were –48·6% (95% CI –58·3 to –38·9) versus placebo, –27·9% (–37·5 to –18·4) versus ezetimibe, and –16·8% (–26·4 to –7·1) versus obicetrapib.
Abstractreviewer’s wording
supportedReviewer 1
The FDC was generally well tolerated with similar adverse event rates to monotherapies.
Adverse event rates were similar across active groups and lowest with placebo, supporting the claim of tolerability.
Evidence: Adverse event rates: FDC 52 (51%), obicetrapib 55 (54%), ezetimibe 54 (53%), placebo 38 (37%).
“Adverse event rates were similar in the FDC (52 [51%] of 102), obicetrapib (55 [54%] of 102), and ezetimibe (54 [53%] of 101) groups and lowest with placebo (38 [37%] of 102).”
AbstractFind in source
supportedReviewers 1, 2
The FDC could improve LDL cholesterol management in patients with pre-existing or high risk for ASCVD.
The claim is appropriately framed as a potential benefit based on the observed LDL reduction, not overstating clinical outcomes.
Evidence: The interpretation states the FDC 'could improve LDL cholesterol management' based on the significant LDL reduction.
“This oral, single-pill therapy could improve LDL cholesterol management in patients with pre-existing or high risk for ASCVD.”
AbstractFind in source
supportedReviewer 2
The FDC of obicetrapib and ezetimibe significantly reduced LDL cholesterol compared with placebo.
The primary endpoint analysis shows a statistically significant reduction with a 95% CI that excludes zero.
Evidence: Primary endpoint: –48·6% (95% CI –58·3 to –38·9, p<0·0001) vs placebo.
At day 84, the difference in the reduction of LDL cholesterol concentrations in the obicetrapib–ezetimibe FDC group was –48·6% (95% CI –58·3 to –38·9, p<0·0001) compared with the placebo treatment group.
Results ¶3reviewer’s wording
supportedReviewer 2
The FDC was well tolerated with no increased adverse effects compared with monotherapies.
Adverse event rates were similar across active groups and higher than placebo, but no significant differences were reported.
Evidence: Adverse event rates: FDC 52 (51%), obicetrapib 55 (54%), ezetimibe 54 (53%), placebo 38 (37%).
“The incidence of any adverse event was lowest in the placebo group (38 [37%] of 102) and generally similar between the obicetrapib–ezetimibe FDC (52 [51%] of 102), obicetrapib monotherapy (55 [54%] of 102), and ezetimibe monotherapy (54 [53%] of 101) groups.”
Results ¶6Find in source
supportedReviewer 2
The FDC provides nearly 50% LDL cholesterol lowering compared with placebo.
The primary endpoint directly supports this claim.
Evidence: Primary endpoint: –48·6% (95% CI –58·3 to –38·9).
At day 84, percent differences in LDL cholesterol reduction with the FDC were –48·6% (95% CI –58·3 to –38·9) versus placebo.
Abstractreviewer’s wording

Premise concern: surrogate not validated for clinical benefit.

INADEQUATESurrogate endpoint
The primary efficacy claim is based on LDL cholesterol reduction, a surrogate biomarker for cardiovascular outcomes. Although the paper cites prior evidence linking LDL cholesterol reduction to reduced ASCVD events, it does not demonstrate target engagement (e.g., PK/PD) at the tested dose in this trial, and the surrogate-to-clinical-outcome link is not validated within this study. The claim of clinical benefit is inferred from LDL lowering.
“Combination therapy of obicetrapib and ezetimibe significantly reduced LDL cholesterol. This oral, single-pill therapy could improve LDL cholesterol management in patients with pre-existing or high risk for ASCVD.”
Find in source
ADEQUATEEffect size
The effect size is large and clinically meaningful: a 48.6% reduction in LDL cholesterol versus placebo, with 71% of FDC-treated patients achieving LDL <1.4 mmol/L, a threshold recommended by ESC/EAS guidelines. The paper explicitly anchors this to clinical meaningfulness by referencing guideline targets and prior outcome trials.
“The FDC of obicetrapib and ezetimibe provided nearly 50% LDL cholesterol lowering compared with placebo and was generally well tolerated across 84 days.”
Find in source

Data authenticity concerns

1 finding · worst low

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

3 integrity concerns flagged (0 high).

lowother
The trial profile shows 407 randomized, but the sum of the four group sizes is 102+102+101+102=407, which is consistent. No issue.
“407 randomly assigned”
Figure 1Find in source

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

The introduction cites prior trials of LDL-lowering drugs and a meta-analysis of statin trials, and discusses the unmet need for oral therapies. The rationale for the FDC is based on prior phase 2 studies of obicetrapib and ezetimibe. Limitations of prior CETP inhibitor trials are acknowledged, and the study design addresses some of these.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with prior work cited and a logical rationale for the study.

Evidence

“Clinical trials of several classes of LDL cholesterol-lowering drugs have shown consistent reductions in major adverse cardiovascular events.”

Introduction ¶1Find in source

paraphrase[Introduction, paragraph 2]

“Obicetrapib is an orally administered, selective CETP inhibitor that significantly reduced LDL cholesterol in small phase 2 studies in participants without ASCVD when administered as monotherapy or in combination with ezetimibe.”

paraphrase[Discussion, paragraph 4]

“In the first phase 3 cardiovascular outcome trial of a CETP inhibitor, treatment with torcetrapib increased morbidity and mortality, most likely as a consequence of off-target toxicity attributed to an aldosterone-like effect with an increase in systolic blood pressure of 5·4 mm Hg.”

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with prior work cited and a logical rationale for the study.

Evidence

paraphrase[Introduction, paragraph 1]

“A large meta-analysis of statin drug trials demonstrated a 22% reduction in cardiovascular events for each 1 mmol/L (38·7 mg/dL) reduction in LDL cholesterol concentration.”

paraphrase[Introduction, paragraph 2]

“ROSE2 was a randomised phase 2 trial of obicetrapib plus ezetimibe for LDL cholesterol reduction, and provided initial data regarding the LDL cholesterol-lowering efficacy of obicetrapib plus ezetimibe in 97 patients with dyslipidaemia.”

Research in contextFind in source

Randomization was computer-generated with a permuted block design, and blinding was achieved with identical tablets/capsules. A power analysis was performed with a sample size of 95 per group. Inclusion/exclusion criteria were pre-specified. The analysis population (ITT) and missing data imputation were defined. The trial is a human RCT, so replicate_distinction, controls, and independent_replication are not applicable.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with adequate randomization, blinding, power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

paraphrase[Methods, Randomisation and masking]

“Randomisation was computer-generated by a contract research organisation through the ClinTrak Interactive Response Technology system. A permuted block design was used (block size of 8).”

“Masking was achieved by the use of identical tablets and capsules such that study investigators and participants could not determine whether they contained active drug or placebo.”

MethodsFind in source

paraphrase[Methods, Statistical analysis]

“Assuming a standard deviation of 25% at a one-sided significance level of 0·025, a sample size of 95 participants per treatment group (380 total) was estimated to provide more than 90% power to detect a 30% difference in LDL cholesterol reduction for the FDC treatment group compared with the placebo group”

PASSReviewer 2· 95% conf

The trial design is rigorous with clear randomization, blinding, power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

paraphrase[Methods, Randomisation and masking]

“Randomisation was computer-generated by a contract research organisation through the ClinTrak Interactive Response Technology system. A permuted block design was used (block size of 8).”

“Participants, investigators, academic leadership, the contract research organisation, and the sponsor were masked to treatment allocation and all lipid results during the trial until all study-related visits and assessments were completed and the database was locked.”

MethodsFind in source

paraphrase[Methods, Statistical analysis]

The paper reports sex, age, race, ethnicity, and comorbidities in Table 1. Both sexes are enrolled, so sex_justified is not applicable. Age and health status are reported. Species/strain and housing conditions are not applicable for a human trial.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and baseline characteristics are well reported, including sex, age, and health status.

Evidence

paraphrase[Results, paragraph 1]

“The median age of participants was 68·0 years (IQR 62·0–73·0), 79 (19%) were at least 75 years of age, 177 (43%) were female”

paraphrase[Table 1]

“Race: White 86 (84%) ... Black or African American 14 (14%) ... Ethnicity: Hispanic or Latino 4 (4%)”

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, race, and comorbidities.

Evidence

paraphrase[Table 1]

“Median age (IQR), years 68·0 (63·0–72·0) 67·0 (61·0–74·0) 68·0 (64·0–73·0) 67·5 (62·0–72·0) Sex Female 48 (47%) 33 (32%) 45 (45%) 51 (50%)”

“Race White 86 (84%) 85 (83%) 82 (81%) 84 (82%) Black or African American 14 (14%) 15 (15%) 13 (13%) 17 (17%)”

Table 1Find in source

“History of ASCVD 72 (71%) 76 (75%) 67 (66%) 65 (64%)”

Table 1Find in source

The protocol was approved by a named central ethics committee (Advarra) with a reference number. Written informed consent was obtained from all participants. The study was conducted in accordance with the Declaration of Helsinki.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethics approval and informed consent are adequately reported.

Evidence

“The protocol and amendments were approved by a central ethics committee (Advarra) for all sites, with initial approval on Sept 28, 2023 (trial reference number Pro00074209).”

MethodsFind in source

“All participants provided written informed consent before undergoing any study procedures.”

MethodsFind in source

“This study was conducted in accordance with ethical principles derived from the Declaration of Helsinki and international ethical guidelines from the Council for International Organizations of Medical Sciences.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethics approval and informed consent are clearly documented.

Evidence

“The protocol and amendments were approved by a central ethics committee (Advarra) for all sites, with initial approval on Sept 28, 2023 (trial reference number Pro00074209).”

MethodsFind in source

“All participants provided written informed consent before undergoing any study procedures.”

MethodsFind in source

The drugs are named with doses and regimen. The statistical software (SAS version 9.4) is identified. No antibodies, cell lines, or other bench reagents are used, so those criteria are not applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational product (obicetrapib and ezetimibe) is adequately identified, and statistical software is named.

Evidence

paraphrase[Methods, Randomisation and masking]

“obicetrapib 10 mg plus ezetimibe 10 mg FDC, obicetrapib 10 mg monotherapy, ezetimibe 10 mg monotherapy, or matching placebo”

“Statistical analyses were performed using SAS version 9.4.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational product (obicetrapib and ezetimibe) is identified with dose and regimen, and statistical software is identified.

Evidence

paraphrase[Methods, Randomisation and masking]

“Participants were randomly assigned in a 1:1:1:1 ratio to receive once per day orally administered FDC of obicetrapib 10 mg plus ezetimibe 10 mg, obicetrapib 10 mg monotherapy, ezetimibe 10 mg monotherapy, or matching placebo.”

“Statistical analyses were performed using SAS version 9.4.”

Statistical analysisFind in source

The primary analysis used ANCOVA with baseline LDL as covariate. Exact p-values are reported for primary endpoints. Effect sizes with 95% CIs are reported. Missing data imputation is described. The statistical software is identified. Data presentation includes individual data points (waterfall plots) and per-group n. Mathematical plausibility checks were not applicable due to continuous outcomes and large N.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well reported, with exact p-values and confidence intervals.

Evidence

“An ANCOVA model with a fixed effect for the treatment group and a covariate of baseline LDL cholesterol was used to assess the primary efficacy parameter”

Statistical analysisFind in source

paraphrase[Results, paragraph 2]

“At day 84, the difference in the reduction of LDL cholesterol concentrations in the obicetrapib–ezetimibe FDC group was –48·6% (95% CI –58·3 to –38·9, p<0·0001)”

“Each vertical bar represents the percent change in LDL cholesterol measured by preparative ultracentrifugation for an individual patient in the treatment group from baseline to day 84”

Figure 3Find in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and confidence intervals for primary endpoints.

Evidence

paraphrase[Methods, Statistical analysis]

“An ANCOVA model with a fixed effect for the treatment group and a covariate of baseline LDL cholesterol was used to assess the primary efficacy parameter.”

paraphrase[Results, paragraph 3]

“At day 84, the difference in the reduction of LDL cholesterol concentrations in the obicetrapib–ezetimibe FDC group was –48·6% (95% CI –58·3 to –38·9, p<0·0001) compared with the placebo treatment group.”

“Primary endpoint: least-squares mean percent difference in LDL cholesterol reduction (95% CI) Obicetrapib plus ezetimibe FDC NA –16·8 (–26·4 to –7·1) –27·9 (–37·5 to –18·4) –48·6 (–58·3 to –38·9)”

Table 2Find in source

The data sharing statement says there is no plan to share individual participant data due to consent limitations, which is acceptable for patient data, but it does not provide a mechanism for data access requests. No code is shared, but the analysis used standard statistical software (SAS), so code sharing may not be applicable.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

Data availability statement is present but vague, and no code is shared.

Evidence

“There is no plan to share individual participant data due to limitations of patient consent.”

Data availabilityFind in source

WARNReviewer 2· 80% conf

Data availability statement is present but vague, and no code is shared.

Evidence

“There is no plan to share individual participant data due to limitations of patient consent.”

Data availabilityFind in source

The trial is registered (NCT06005597). Methods are detailed. Limitations are discussed. Conclusions are proportional to the evidence. Funding and conflicts of interest are declared. The paper does not explicitly reference a reporting guideline (e.g., CONSORT), but the trial profile is provided.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial is registered, methods are complete, limitations are discussed, and conclusions are proportional.

Evidence

“The trial is registered with ClinicalTrials.gov (NCT06005597) and is completed.”

MethodsFind in source

“The trial has several limitations. First, most participants were White; however, the trial enrolled 14% Black or African American participants as well as 43% women, who have traditionally been under-represented in clinical trials. Second, the follow-up period was only 84 days”

Discussion ¶8Find in source

“ASt, DK, ALN, JK, MDa, and MDi are employees of NewAmsterdam Pharma.”

Declaration of interestsFind in source

PASSReviewer 2· 90% conf

The trial is registered, methods are complete, limitations are discussed, and funding/COI are disclosed.

Evidence

“The trial is registered with ClinicalTrials.gov (NCT06005597) and is completed.”

MethodsFind in source

Discussion ¶7Find in source

“Funding NewAmsterdam Pharma.”

FundingFind in source

Registered (2 IDs: ClinicalTrials.gov). No reporting guideline cited.

ClinicalTrials.gov

NCT06005597

ClinicalTrials.gov

NCT05202509

Broken references and links

None found · partly checked

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Nothing surfaced — but not everything feeding this category ran (missing: data/code link verification), so read this as a partial clean bill.

Checked 33 references by DOI: 1 verified — 32 no DOI (shown, not verified).

NO DOI
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Ezetimibe added to statin therapy after acute coronary syndromes
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Evolocumab and clinical outcomes in patients with cardiovascular disease
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Alirocumab and cardiovascular outcomes after acute coronary syndrome
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Bempedoic acid and cardiovascular outcomes in statin-intolerant patients
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Interpretation of the evidence for the efficacy and safety of statin therapy
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Healthcare professionals’ perspectives on the use of PCSK9 inhibitors in cardiovascular disease: an in-depth qualitative study
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: results of a healthcare provider survey conducted by the National Lipid Association
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Effects of anacetrapib in patients with atherosclerotic vascular disease
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Evacetrapib and cardiovascular outcomes in high-risk vascular disease
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Effects of torcetrapib in patients at high risk for coronary events
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Effects of dalcetrapib in patients with a recent acute coronary syndrome
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: a randomized phase 2 trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Ezetimibe
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Contemporary national patterns of eligibility and use of novel lipid-lowering therapies in the United States
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Lipid treatment and goal attainment characteristics among persons with atherosclerotic cardiovascular disease in the United States
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
LDL cholesterol targets rarely achieved in familial hypercholesterolemia patients: a sex and gender-specific analysis
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Patient-reported reasons for declining or discontinuing statin therapy: insights from the PALM registry
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: results from the VOYAGER meta-analysis
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Association between achieved low-density lipoprotein cholesterol levels and long-term cardiovascular and safety outcomes: an analysis of FOURIER-OLE
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Association of apolipoprotein B-containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis: distinguishing between particle concentration, type, and content
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Cardiovascular outcome study to evaluate the effect of obicetrapib in patients with cardiovascular disease (PREVAIL)
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).

Copyediting

4 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 4 minor suggestions below.

4 copyedit issues flagged: mostly consistency, typo.

MINORconsistencyAbstract, Methods
“ASVCD”
→ Change to 'ASCVD'
Typo in abstract: 'ASVCD' should be 'ASCVD'.
MINORconsistencyTable 1, footnote
“38·67 mg/dL = 1 mmol/L”
→ Ensure consistent conversion factor notation
Conversion factor is stated, but check consistency with other tables.
MINORtypoAbstract, Methods
“ASVCD”
→ ASCVD
Typo in the abstract: 'ASVCD' should be 'ASCVD'.
MINORconsistencyResults, paragraph 3
“–31·9% (–41·6 to –22·1, p<0·0001)”
→ Ensure consistent ordering of CI bounds (low to high) across all endpoints.
In the abstract, the CI is reported as (22·1 to 41·6) for the same endpoint, which is reversed. Check consistency.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and well-reported; an informed reader should weigh the minor data-sharing limitation and the small internal inconsistencies (CI sign in abstract, missing CONSORT reference) as minor issues that do not undermine the main conclusions. No erratum is warranted for the CI sign inconsistency, but the authors should consider clarifying the data availability mechanism and explicitly citing CONSORT in any future correspondence or revision.

1.
HIGHdata code
Revise the Data sharing statement to provide a concrete mechanism for accessing de-identified aggregate data, e.g., 'De-identified aggregate data will be made available upon reasonable request to the corresponding author, subject to approval by the sponsor and a data sharing agreement.'
The current statement is vague and does not offer any avenue for data access, which is a common reviewer concern for clinical trials.
2.
HIGHreporting
Explicitly state adherence to CONSORT reporting guidelines in the Methods or Acknowledgments, and consider including a CONSORT flow diagram in the main text.
The paper follows a CONSORT-like structure but does not explicitly reference the guideline, which is a minor reporting gap that reviewers may flag.
3.
MEDIUMcopyedit
Fix the typo 'ASVCD' to 'ASCVD' in the Abstract (Methods section).
The copyedit pass flagged this typo, which could undermine the paper's professionalism.
4.
MEDIUMcopyedit
Ensure consistent ordering of confidence interval bounds across all endpoints; specifically, the abstract reports the obicetrapib monotherapy vs placebo CI as (22·1 to 41·6) while the results section reports it as (–41·6 to –22·1).
The sign inconsistency in the CI is confusing and could be misinterpreted; standardize to low-to-high ordering with consistent signs.
5.
MEDIUMreporting
Clarify the role of the sponsor in data analysis and publication to address potential bias.
The sponsor is the funder and several authors are employees; a clear statement on sponsor involvement in analysis and publication is important for transparency.
6.
LOWdata code
Consider depositing de-identified aggregate data or summary statistics in a public repository (e.g., Zenodo) to enhance transparency.
Even if individual participant data cannot be shared, aggregate data would improve reproducibility and public trust.
7.
LOWdata code
If any custom analysis code was used, share it in a public repository (e.g., GitHub) with a DOI.
Sharing code, even for standard analyses, can enhance reproducibility and is increasingly expected.
8.
LOWcopyedit
Check consistency of the LDL conversion factor notation (38·67 mg/dL = 1 mmol/L) across all tables and text.
The copyedit pass noted potential inconsistency in conversion factor notation; ensure it is uniform.

Full text (58,792 chars)Analyzed: Aug 15, 2026

RigorReviewer 1

RigorReviewer 2

RigorPre-Submission Reviewer

CopyeditAgent Scribe

CitationsCitation Integrity

StatisticsStatistics Consistency

PreregistrationDeterministic check· no model (rule-based)

The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”

How stars are deducted

Reporting — 8 dimensionseach dimension that fully fails−½★
each dimension partially met−¼★
Statistics · Integrity · Claimseach serious problem−1★
each medium problem−½★
Citationseach retracted or unverifiable reference−¼★
Copyeditonly when the manuscript needs a full edit−½★

The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.

The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.

The eight reporting dimensions

Scientific PremisePrior work, rationale, and how it addresses gaps.

Study Design & RigorRandomization, blinding, power, controls, replication.

Biological VariablesSex, age, species/strain, housing, demographics.

Ethical ApprovalsIRB/IACUC approval, informed consent, regulatory compliance.

Key ResourcesAntibodies, cell lines, organisms, software — identified with persistent IDs.

Statistical ReportingNamed tests, exact p-values, effect sizes, plausible summary stats.

Data & Code AvailabilityAvailability statements, repositories, accession numbers, shared code.

Reporting TransparencyMethods, registration, guidelines, outcomes, limitations, funding/COI.

Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.

This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.

Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial.

Sarraju A, Brennan D, Hayden K, Stronczek A, Goldberg AC, Michos ED, McGuire DK, Mason D, Tercek G, Nicholls SJ, Kling D, Neild AL, Kastelein J, Davidson M, Ditmarsch M, Nissen SE

DOI

10.1016/S0140-6736(25)00721-4

Record issued

2026-08-15

Engine

7.39.0

Exported

2026-09-20